Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline vs. Varenicline Plus Bupropion for Smoking Cessation
NCT00943618Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2010
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nicotine dependence comparing Group 1 (Varenicline + Bupropion), Group 2 (Varenicline + Placebo) and Group 3 (Placebo + Placebo) (3 arms). Primary endpoint: Smoking Abstinence at 12 Months. Started May 2010; status: completed.
02
Drugs
bupropionvarenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT00943618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00943618.